Lexon buys Cancer Diagnostics to strengthen test portfolio
This article was originally published in Clinica
Executive Summary
Development-stage company Lexon is to gain access to a blood test for lung cancer through the acquisition of UTEK subsidiary Cancer Diagnostics, for an undisclosed amount. The Tulsa, Oklahoma-based company already has exclusive, worldwide rights to a blood test for colon cancer.